WebSep 26, 2024 · Trichomegaly is defined as an increase in the length (above 12 mm), thickness, stiffness, curling, and pigmentation of existing eyelashes. The term … WebSep 21, 2016 · Whether eyelash trichomegaly correlates with clinical response of lung cancer to EGFR inhibitors or whether it occurs as an unrelated adverse event remains to …
Eyelash trichomegaly following treatment with erlotinib in a …
WebMar 15, 2009 · Abstract. Medications belonging to the group of epidermal growth factor (EGFR) inhibitors are currently in widespread use for the treatment of epithelial malignancies. Many cutaneous side effects are known to develop as a result of the use of these agents. Trichomegaly is a newly described side effect, consisting of premature … WebApr 11, 2011 · Trichomegaly, the excessive growth of eyelashes, is a relatively rare cosmetic disorder that has been described as part of congenital conditions, in HIV patients, associated with an autoimmune disease, or secondary to certain drugs such as topical ocular prostaglandin analogs, immunomodulators, anticonvulsivants, zidovudine, and … inchcape rock poem summary
Dermatology Case Reports Case Report - iomcworld.com
WebMar 1, 2015 · Cetuximab and erlotinib more commonly induce eyelash trichomegaly than panitumumab and gefitinib. 68. Immunomodulatory medications as well may induce trichomegaly. Eyelash trichomegaly may occur in the minority of patients treated with systemic cyclosporine and tacrolimus 69; rarer still is the induction of trichomegaly with … Webeyelash trichomegaly is not a drug-limiting side effect. Recently, with the wide use of erlotinib in NSCLC patients, an increased number of cutaneous adverse effects, including acneiform rash or pruritus, have been observed (6). Erlotinib-associated eyelash trichomegaly has been reported only in a small number of case reports (4,5,15-17). To ... WebCarser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006;1(9):1040–1041. 15. Brandi G, Venturi M, Dika E, Maibach H, Patrizi A, Biasco G. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy. inchcape rock lighthouse